Twist Bioscience faces earnings test as profit path comes into view
Twist Bioscience (TWST) reports Q4 earnings with investors watching for profitability. The company expects $456M-$457M in full-year revenue and adjusted EBITDA breakeven. Analysts forecast a 38-cent loss per share on $123.59M revenue, with estimates down 39% recently. The stock has a mean price target of $168.25, down from October highs. AI-driven drug discovery and market share dynamics are key focus areas.
How this was made
The 30-second read
Why it matters
The fresh guidance and earnings results provide the first concrete data point on the company's profitability trajectory, making the article a primary source of material information.
Market read
Guidance on profitability and revenue targets creates a near‑term trading catalyst for TWST and may influence sentiment in the broader biotech sector.
What to watch
Potential supply‑chain constraints and competition from larger DNA synthesis players could hinder margin expansion.
Background
Twist Bioscience is a synthetic DNA manufacturer that has been under pressure after a short‑seller report and recent analyst downgrades.
Ticker impact
Twist Bioscience reported Q4 results and provided full-year revenue guidance of $456‑$457M and adjusted EBITDA breakeven guidance for the quarter.
potential upside if the company hits breakeven, but likely pressure if earnings fall short of guidance
Investors will focus on the profitability milestone; the guidance is new and material, creating a clear decision point.
Market effects
Positive guidance may lift other synthetic‑DNA and biotech suppliers as the AI‑driven drug discovery market expands.
US biotech sector could see modest gains if Twist's profitability path is validated.
Limited to biotech investors; no broader macro impact.
Counterpoint
If the company fails to achieve EBITDA breakeven, the stock could face a sharp decline despite the guidance.
Key entities
- companyTwist Bioscience Corp
Synthetic DNA manufacturer reporting Q4 results and guidance.
- companyEli Lilly
Partner in antibody characterization data services.
- companyAmazon Web Services
Partnered with Twist for Amazon Bio Discovery.
